Physician profile
Brooke E Wehbe
NPI 1902381544
$1,940.01
in general payments reported to CMS, 2019-2025
11 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $172 · 2023: $433 · 2024: $937 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,489 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,488.99 |
| Education | $163.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $526.41 | 2023-2025 | Myrisk |
| Jazz Pharmaceuticals INC. | $499.30 | 2021-2024 | |
| Genzyme Corporation | $195.88 | 2023 | |
| Daiichi Sankyo INC. | $185.73 | 2024 | Enhertu |
| Pfizer INC. | $148.28 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $140.32 | 2024-2025 | Enhertu, Imfinzi |
| Seagen INC. | $113.89 | 2023 | Adcetris |
| Janssen Biotech, INC. | $59.87 | 2024 | Erleada, Akeega, Rybrevant |
| Abbvie INC. | $35.62 | 2022 | |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $14.71 | 2024 | Opdivo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Wehbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.